Trial Profile
Single center study of Eculizumab in Highly Sensitized Patients Undergoing Heart Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Heart transplant rejection
- Focus Therapeutic Use
- 15 Jun 2022 New trial record
- 30 Apr 2022 Results presented at the 42nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation